March 2025, Vol 15, No 3
The question remains: after 10 years of biosimilar availability in the
United States and 20 years in Europe, are we there yet? Read More ›
A recent US-based study presented at the San Antonio Breast Cancer Symposium examined racial disparities in biomarker prevalence, treatment patterns, and clinical outcomes among Black and White patients with hormone receptor-positive/HER2-negative metastatic breast cancer who underwent next-generation sequencing. Read More ›
Clinical practice has evolved over time, and the doctor’s tools used in the past may no longer be the tools that are regularly utilized today. However, that brings up the question: what tools will healthcare utilize today or in the future? Read More ›
Next-generation sequencing of circulating tumor DNA (ctDNA) is integral to optimal cancer treatment, as exploring ctDNA can provide a complete picture of a tumor’s genetic landscape and can thus help guide treatment for the patient. The IMAGE II study (NCT02965755) investigated the clinical utility of serial ctDNA assessment in patients with metastatic breast cancer. Read More ›
Machine learning may hold promise for analyzing cells co-expressing MYC and BCL2 but lacking BCL6 in diffuse large B-cell lymphoma, which can be associated with poorer survival patterns, according to a study presented at the 66th ASH Annual Meeting & Exposition held in San Diego, CA. Read More ›
Later cancer treatment initiation and fewer treatment options once treatment starts are just some of the impacts of longer driving distances to treatment, according to researchers reporting in a study presented at the 66th Annual Meeting & Exposition held in San Diego, CA. Read More ›
US-Based Clinical Trials Actively Recruiting in Cancers of the Blood
Clinical trial recruitment and retention remain challenges in the quest to bring innovative therapies to all patients in need. In oncology, therapies continue to evolve, yet researchers are frequently faced with low trial participation,
particularly among minority groups. Read More ›
Fam-trastuzumab deruxtecan-nxki (Enhertu; Daiichi Sankyo) has been approved by FDA officials for use in patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, who have progressed on one or more endocrine therapies in the metastatic setting. Read More ›
On January 17, 2025, the FDA approved datopotamab deruxtecan-dlnk (Datroway; Daiichi Sankyo) for adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer. Read More ›
The FDA has approved sotorasib (Lumakras; Amgen) with panitumumab (Vectibix; Amgen) for adult patients with KRAS G12C–mutated metastatic colorectal cancer (CRC), as determined by an FDA-approved test, who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. Read More ›
Acalabrutinib (Calquence; AstraZeneca) with bendamustine and rituximab has been greenlit for adults with previously untreated mantle cell lymphoma who are ineligible for autologous hematopoietic stem-cell transplantation. Read More ›
In the healthcare industry, financial collections are an unavoidable aspect of maintaining a sustainable practice. However, the sensitive nature of medical services requires a delicate balance between pursuing payments and preserving the patients’ trust and satisfaction. Successfully navigating this balance is crucial for the practice’s long-term success.
Read More ›